Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in Vivo

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2653-2656

  He, Zhengxiang ^a   Qin, Li ^a   Chen, Lili ^a   Peng, Nanzheng ^a   You, Jianlan ^a   Chen, Xiaoping ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHLOROQUINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NONHUMAN; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALARIA; MICE; NELFINAVIR; OLIGOPEPTIDES; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PYRIDINES; PYRIMIDINONES; RITONAVIR; SAQUINAVIR;

EID: 46249121628     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01329-07     Document Type: Article

References (18)

1. Andrews, K. T., D. P. Fairlie, P. K. Madala, J. Ray, D. M. Wyatt, P. M. Hilton, L. A. Melville, L. Beattie, D. L. Gardiner, R. C. Reid, M. J. Stoermer, T. Skinner-Adams, C. Berry, and J. S. McCarthy. 2006. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50:639-648.
2. Canfield, C. J., M. Pudney, and W. E. Gutteridge. 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80:373-381.
3. Deloron, P., L. K. Basco, B. Dubois, C. Gaudin, F. Clavier, J. Le Bras, and F. Verdier. 1991, In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine. Antimicrob. Agents Chemother. 35:1338-1342.
4. Dubois, V. L., D. F. Platel, G. Pauly, and J. Tribouley-Duret. 1995. Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. Exp. Parasitol. 81:117-124.
5. Fidock, D. A., P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug. Discov. 3:509-520.
6. Fivelman, Q. L., I. S. Adagu, and D. C. Warhurst. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48:4097-4102.
7. Henry, M., S. Alibert, E. Orlandi-Pradines, H. Bogreau, T. Fusai, C. Regier, J. Barbe, and B. Pradines. 2006. Chloroquine resistance reversal agents as promising antimalarial drugs. Curr. Drug Targets 7:935-948.
8. Hunt, P., P. V. Cravo, P. Donleavy, J. M. Carlton, and D. Walliker. 2004. Chloroquine resistance in Plasmodium chabaudi: are chloroquine-resistance transporter (crt) and multi-drug resistance (mdr1) orthologues involved? Mol. Biochem. Parasitol. 133:27-35.
9. Ikezoe, T., Y. Hisatake, T. Takeuchi, Y. Ohtsuki, Y. Yang, J. W. Said, H. Taguchi, and H. P. Koeffler. 2004. HIV-1 protease inhibitor, ritonavir, a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 64:7426-7431.
10. Lambros, C., and J. P. Vanderberg. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420.
11. Meierjohann, S., R. D. Walter, and S. Müller. 2002. Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochem. J. 368:761-768.
12. Parikh, S., J. Gut, E. Istvan, D. E. Goldberg, D. V. Havlir, and P. J. Rosenthal. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985.
13. Savarino, A., M. B. Lucia, E. Rastrelli, S. Rutella, C. Golotta, E. Morra, E. Tamburrini, C. F. Perno, J. R. Boelaert, K. Sperber, and R. Cauda. 2004. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J. Acquir. Immune Defic. Syndr. 35:223-232.
14. Skinner-Adams, T. S., K. T. Andrews, L. Melville, J. McCarthy, and D. L. Gardiner. 2007. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51:759-762.
15. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, P. M. Hilton, and K. T. Andrews. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000.
16. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
17. Valderramos, S. G., and D. A. Fidock. 2006. Transporters involved in resistance to antimalarial drugs. Trends. Pharmacol. Sci. 27:594-601.
18. Ward, S. A., and P. G. Bray. 2001. Is reversal of chloroquine resistance ready for the clinic? Lancet 357:904.